Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 2b randomized double-blind placebo-controlled study of verinurad plus allopurinol in chronic kidney disease with hyperuricemia
MOH_2019-08-05_007259Phase 2Not yet recruiting
- Sponsor
- AstraZeneca
- Start
- Jul 2019
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial of verinurad and allopurinol in chronic kidney disease (CKD) and hyperuricemia (5 arms), sponsored by AstraZeneca. Primary endpoint: Primary efficacy endpoint. Planned start Jul 2019; status: not yet recruiting.
02
Drugs
verinuradallopurinol
03
Conditions
chronic kidney disease (CKD)hyperuricemia
Beyond the preview
Go deeper on MOH_2019-08-05_007259.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on MOH_2019-08-05_007259.